| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |